The next debate on embryo science
By Editorial,
Nature Biotechnology
| 08. 02. 2021
The International Society for Stem Cell Research has called for broad public dialogue on the ethics of human embryo research beyond 14 days post-fertilization. National jurisdictions should seize the moment.
A longstanding prohibition against culturing human embryos for more than 14 days is now open for discussion, according to revised research guidelines released in May by the International Society for Stem Cell Research (ISSCR). The society’s change in position was prompted by recent advances in embryo culture methods that promise to deepen understanding of human development at the stage when the embryo implants in the uterus—knowledge that may lead to new therapies for infertility and miscarriage. The ISSCR is to be commended for encouraging ethical reflection on extending the 14-day rule before the world is caught off guard by an embryo experiment that goes beyond the accepted time frame. It is now up to interested parties in national scientific, political, ethics and religious communities to take up the ISSCR’s challenge.
In 1978, the birth of the first baby created through in vitro fertilization (IVF) was met with a storm of controversy. IVF provoked deep concerns and anxieties about the wisdom of tampering with the natural order of reproduction. Once human procreation was unlinked from coitus, impossible things became possible: women...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...